San Diego Business Journal’s Post

📰 #NSCLC | ASCO24: J&J's subQ Rybrevant matches efficacy, shrinks infusion time in Phase III trial "The PALOMA-3 trial, presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting, is testing the SC formulation of J&J's EGFR/MET-targeting bispecific antibody in 418 patients with EGFR-mutated, advanced or metastatic non-small-cell lung cancer (NSCLC) and exon 19 deletion or L858R mutations [...]" https://hubs.ly/Q02zY4Bq0 FirstWord Pharma

[ 🔔 📢 NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?] The Cancer Drug Development Forum (CDDF) is delighted to announce that the White Paper has been developed following its ‘Histology Independent Drug Development – Is This the Future for Cancer Drugs?’ workshop, which took place on 14-15th November 2022, in Amsterdam. The hybrid meeting was set up to explore the current landscape of histology independent drug development, review the current regulatory landscape and propose recommendations for improving the conduct of future trials. 🔔📑 Read the full article published in Cancer Treatment Reviews here: https://lnkd.in/ebgtynQA #Cancer #oncologytrials #HistologyIndependent #Tumour #Biomarkers #DataSharing

During my college and med school years, the #HumanGenomeProject was in full swing. As a self-proclaimed nerd, I was thrilled by the potential of sequencing the human genome. Last week, I felt that same excitement at an internal meeting discussing the Cell Surfaceome. This initiative holds immense promise for oncology drug development, particularly in the use of radioligands, antibody-drug conjugates (ADCs), and other innovative therapies. For those interested in learning more, this article is a great place to start: Elucidating the Cell Surfaceome to Accelerate Oncology Drug Development. #RLT #AACR #DrugDevelopmemt #Oncology #Cancer #Surfaceome Novartis https://lnkd.in/gvaUeDst

In this study, our collaborators at Grey Wolf Therapeutics have shown that inhibition of ERAP2 modulates the presented HLA class I #immunopeptidome. 🎉 Grey Wolf leveraged our #TrueDiscovery® Immunopeptidome Profiling services to identify an increase in 9-mers and a reduction in 8-mers HLA I peptides upon inhibition of ERAP2. 🚀 Download the poster. https://lnkd.in/dZuaifND #Oncology #Proteomics #MassSpectrometry✨

I am excited to see, what MS-based proteomics can deliver for immunopeptidomics drug development: Measurement of global immunopeptide length shift. Since often, immunopeptides are the ultimate readout and effectors, their direct and comprehensive measurement is key. I am looking forward to more impact! #immunooncology #immunology #massspectrometry #proteomics #immunopeptidomics

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/eaxfqX showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/7Y36P0 🤝 #ChemoMetec #NucleoCounter #IovanceBiotherapeutics #Cellcounting

Visit our AACR 2024 poster with Sanofi to learn about our recent study investigating spatiotemporal tumor immune modulation with different mono- or combined cancer therapeutics. Our research included the use of antibody I/O agents at different time points and drug concentrations that were introduced simultaneously into a tumor with the Kibur NanoNail. Check out the details of this exciting study at the link provided! #AACR2024 #Sanofi #cancerresearch #KiburMedical #NanoNail

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/p9lL05 showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/zxroU6 🤝

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/RmqB6y showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/1sZz4E 🤝

Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/3V8kHA showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/6vpxSK 🤝